Watch for Patients on the Parkinson's Med Nourianz

Istradefylline (Nourianz, NUR-ee-anz) will be the first NON-dopaminergic "adenosine antagonist" for Parkinson's disease.

It's a once-daily add-on for "off" episodes...when scheduled carbidopa/levodopa wears off between doses and symptoms (rigidity, tremor, etc) return, especially as Parkinson's progresses.

But istradefylline doesn't seem to reduce "off" time more than dopaminergic add-ons...COMT inhibitors (entacapone, etc), dopamine agonists (pramipexole, etc), or MAO-B inhibitors (rasagiline, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals